Clinical use and applications of histone deacetylase inhibitors in multiple myeloma

References

• KyleRARajkumarSVMultiple myelomaN Engl J Med2004351181860187315509819
   PubMed Web of Science ®Google Scholar
• National Cancer Institute [webpage on the Internet]SEER Stat Fact Sheets: Myeloma2016 Available from: http://seer.cancer.gov/statfacts/html/mulmy.htmlAccessed March 7, 2016
   Google Scholar
• KristinssonSYLandgrenODickmanPWDerolfARBjorkholmMPatterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003J Clin Oncol200725151993199917420512
   PubMed Web of Science ®Google Scholar
• KumarSKRajkumarSVDispenzieriAImproved survival in multiple myeloma and the impact of novel therapiesBlood20081112516252017975015
   PubMed Web of Science ®Google Scholar
• KumarSKLeeJHLahuertaJJRisk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyLeukemia20122614915721799510
   PubMed Web of Science ®Google Scholar
• SharmaAHeuckCJFazzariMJDNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancerWiley Interdiscip Rev Syst Biol Med2010265466920890963
   PubMed Web of Science ®Google Scholar
• ChapmanMALawrenceMSKeatsJJInitial genome sequencing and analysis of multiple myelomaNature201147146747221430775
   PubMed Web of Science ®Google Scholar
• DimopoulosKGimsingPGronbaekKThe role of epigenetics in the biology of multiple myelomaBlood Cancer J20144e20724786391
   PubMed Web of Science ®Google Scholar
• DimopoulosKGimsingPGrønbaekKAberrant microRNA expression in multiple myelomaEur J Haematol2013919510523586898
   PubMed Web of Science ®Google Scholar
• BentleyGAFinchJTLewit-BentleyARothMThe crystal structure of the nucleosome core particle by contrast variationBasic Life Sci1984271051176712563
   PubMedGoogle Scholar
• MoniotSWeyandMSteegbornCStructures, substrates, and regulators of mammalian sirtuins – opportunities and challenges for drug developmentFront Pharmacol201231622363286
   PubMed Web of Science ®Google Scholar
• KhanOLa ThangueNBDrug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomasNat Clin Pract Oncol2008571472618839006
   PubMedGoogle Scholar
• KhanOLa ThangueNBHDAC inhibitors in cancer biology: emerging mechanisms and clinical applicationsImmunol Cell Biol201290859422124371
   PubMed Web of Science ®Google Scholar
• WittODeubzerHEMildeTOehmeIHDAC family: what are the cancer relevant targets?Cancer Lett200927782118824292
   PubMed Web of Science ®Google Scholar
• GregorettiIVLeeYMGoodsonHVMolecular evolution of the histone deacetylase family: functional implications of phylogenetic analysisJ Mol Biol2004338173115050820
   PubMed Web of Science ®Google Scholar
• LiuTLiuPYMarshallGMThe critical role of the class III histone deacetylase SIRT1 in cancerCancer Res2009691702170519244112
   PubMed Web of Science ®Google Scholar
• JonesPABaylinSBThe fundamental role of epigenetic events in cancerNat Rev Genet2002341542812042769
   PubMed Web of Science ®Google Scholar
• SmithEMBoydKDaviesFEThe potential role of epigenetic therapy in multiple myelomaBr J Haematol200914870271319912222
   PubMed Web of Science ®Google Scholar
• MaesKMenuEValckenborghEVRietIVVanderkerkenKBruynEDEpigenetic modulating agents as a new therapeutic approach in multiple myelomaCancers2013543046124216985
   PubMedGoogle Scholar
• BollatiVFabrisSPegoraroVDifferential repetitive DNA methylation in multiple myeloma molecular subgroupsCarcinogenesis2009301330133519531770
   PubMed Web of Science ®Google Scholar
• AokiYNojimaMSuzukiHGenomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myelomaGenome Med2012410123259664
   PubMed Web of Science ®Google Scholar
• WalkerBAWardellCPChiecchioLAberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myelomaBlood201111755356220944071
   PubMed Web of Science ®Google Scholar
• Martinez-GarciaEPopovicRMinDJThe MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cellsBlood201111721122020974671
   PubMed Web of Science ®Google Scholar
• BritoJLWalkerBJennerMMMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cellsHaematologica200994788619059936
   PubMed Web of Science ®Google Scholar
• WeichertWHDAC expression and clinical prognosis in human malignanciesCancer Lett2009280216817619103471
   PubMed Web of Science ®Google Scholar
• MarquardLGjerdrumLMChristensenIJJensenPBSehestedMRalfkiaerEPrognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphomaHistopathology200853326727718671804
   PubMed Web of Science ®Google Scholar
• SkovVLarsenTSThomassenMIncreased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasmsLeuk Lymphoma201253112312921806350
   PubMed Web of Science ®Google Scholar
• WangJCChenCDumlaoTEnhanced histone deacetylase enzyme activity in primary myelofibrosisLeuk Lymphoma200849122321232719052980
   PubMed Web of Science ®Google Scholar
• MarquardLPoulsenCBGjerdrumLMHistone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomasHistopathology200954668869819438744
   PubMed Web of Science ®Google Scholar
• WeichertWRöskeAGekelerVAssociation of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysisLancet Oncol20089213914818207460
   PubMed Web of Science ®Google Scholar
• WeichertWRöskeANiesporekSClass I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivoClin Cancer Res20081461669167718347167
   PubMed Web of Science ®Google Scholar
• WeichertWDenkertCNoskeAExpression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomasNeoplasia20081091021102718714364
   PubMed Web of Science ®Google Scholar
• ZhangZYamashitaHToyamaTQuantitation of HDAC1 mRNA expression in invasive carcinoma of the breastBreast Cancer Res Treat2005941111616172792
   PubMed Web of Science ®Google Scholar
• MorenoDAScrideliCACortezMADifferential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemiaBr J Haematol2010150666567320636436
   PubMed Web of Science ®Google Scholar
• Van DammeMCrompotEMeulemanNHDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significanceEpigenetics20127121403141223108383
   PubMed Web of Science ®Google Scholar
• MithraprabhuSKalffAChowAKhongTSpencerADysregulated class I histone deacetylases are indicators of poor prognosis in multiple myelomaEpigenetics20149111511152025482492
   PubMed Web of Science ®Google Scholar
• HellerGSchmidtWMZieglerBGenome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cellsCancer Res200868445418172295
   PubMed Web of Science ®Google Scholar
• MitsiadesCSMitsiadesNSMcMullanCJTranscriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implicationsProc Natl Acad Sci U S A200410154054514695887
   PubMed Web of Science ®Google Scholar
• NeriPTagliaferriPdi MartinoMTIn vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitorBr J Haematol200814352053118986388
   PubMed Web of Science ®Google Scholar
• Van LintCEmilianiSVerdinEThe expression of a small fraction of cellular genes is changed in response to histone hyperacetylationGene Expr199652452538723390
   PubMed Web of Science ®Google Scholar
• GraySGQianCNFurgeKGuoXTehBTMicroarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell linesInt J Oncol20042477379515010814
   PubMed Web of Science ®Google Scholar
• PeartMJSmythGKvan LaarRKIdentification and functional significance of genes regulated by structurally different histone deacetylase inhibitorsProc Natl Acad Sci USA20051023697370215738394
   PubMed Web of Science ®Google Scholar
• KaiserMZavrskiISterzJThe effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myelomaHaematologica20069124825116461312
   PubMed Web of Science ®Google Scholar
• KhanSBMaududiTBartonKAyersJAlkanSAnalysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myelomaBr J Haematol200412515616115059137
   PubMed Web of Science ®Google Scholar
• GolayJCuppiniLLeoniFThe histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cellsLeukemia2007211892190017637810
   PubMed Web of Science ®Google Scholar
• CatleyLWeisbergETaiYTNVPLAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myelomaBlood20031022615262212816865
   PubMed Web of Science ®Google Scholar
• FengRMaHHassigCAKD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signalingMol Cancer Ther200871494150518566220
   PubMed Web of Science ®Google Scholar
• CatleyLWeisbergEKiziltepeTAggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsBlood20061083441344916728695
   PubMed Web of Science ®Google Scholar
• LavelleDChenYHHankewychMDe-SimoneJHistone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expressionAm J Hematol20016817017811754398
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSRichardsonPGMolecular sequelae of histone deacetylase inhibition in human malignant B cellsBlood20031014055406212531799
   PubMed Web of Science ®Google Scholar
• MaisoPCarvajal-VergaraXOcioEMThe histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistanceCancer Res2006665781578916740717
   PubMed Web of Science ®Google Scholar
• DeleuSLemaireMArtsJThe effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine modelsLeukemia2009231894190319494837
   PubMed Web of Science ®Google Scholar
• BaiLYOmarHAChiuCFChiZPHuJLWengJRAntitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cellsCancer Chemother Pharmacol201035373379
   Google Scholar
• SchwartzCPalissotVAoualiNValproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell linesInt J Oncol20073057358217273758
   PubMed Web of Science ®Google Scholar
• RosatoRRAlmenaraJAMaggioSCRole of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactionsMol Cancer Ther20087103285329718852132
   PubMed Web of Science ®Google Scholar
• ChenCSWangYCYangHCHistone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylationCancer Res200767115318532717545612
   PubMed Web of Science ®Google Scholar
• FengROtonAMaparaMYAndersonGBelaniCLentzschSThe histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damageBr J Haematol200713938539717910628
   PubMed Web of Science ®Google Scholar
• LeeCKWangSHuangXRyderJLiuBHDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cellsCancer Lett201029623324020447761
   PubMed Web of Science ®Google Scholar
• BakkenistCJKastanMBDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociationNature2003421692249950612556884
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaASantosFPGarcia-ManeroGHistone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemiaLeukemia201125222623521116282
   PubMed Web of Science ®Google Scholar
• PeiXYDaiYGrantSSynergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitorsClin Cancer Res2004103839385215173093
   PubMed Web of Science ®Google Scholar
• DeleuSLemaireMArtsJBortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myelomaCancer Res2009695307531119531653
   PubMed Web of Science ®Google Scholar
• MaesKMenuEVan ValckenborghEVan RietIVanderkerkenKDe BruyneEEpigenetic modulating agents as a new therapeutic approach in multiple myelomaCancers (Basel)20135243046124216985
   PubMedGoogle Scholar
• LemaireMDeleuSde BruyneEvan ValckenborghEMenuEVanderkerkenKThe microenvironment and molecular biology of the multiple myeloma tumorAdv Cancer Res2012110194221704227
   PubMed Web of Science ®Google Scholar
• QianDZWangXKachhapSKThe histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584Cancer Res200464186626663415374977
   PubMed Web of Science ®Google Scholar
• EllisLHammersHPiliRTargeting tumor angiogenesis with histone deacetylase inhibitorsCancer Lett2009280214515319111391
   PubMed Web of Science ®Google Scholar
• LiuTKuljacaSTeeAMarshallGMHistone deacetylase inhibitors: multifunctional anticancer agentsCancer Treat Rev200632315716516516391
   PubMed Web of Science ®Google Scholar
• DongXFSongQLiLZZhaoCLWangLQHistone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptorNeuro Endocrinol Lett20072877578018063935
   PubMed Web of Science ®Google Scholar
• KitazoeKAbeMHiasaMValproic acid exerts anti-tumor as well as antiangiogenic effects on myelomaInt J Hematol200989455719093163
   PubMed Web of Science ®Google Scholar
• DavenportELMooreHEDunlopASHeat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cellsBlood20071102641264917525289
   PubMed Web of Science ®Google Scholar
• BaliPPranpatMBradnerJInhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90J Biol Chem20052802672934
   Google Scholar
• RichonVMGarcia-VargasJHardwickJSDevelopment of vorinostat: current applications and future perspectives for cancer therapyCancer Lett200928020121019181442
   PubMed Web of Science ®Google Scholar
• HideshimaTBradnerJEWongJSmall-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myelomaProc Natl Acad Sci U S A20051028567857215937109
   PubMed Web of Science ®Google Scholar
• SantoLHideshimaTKungALPreclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaBlood20121192579258922262760
   PubMed Web of Science ®Google Scholar
• KikuchiJWadaTShimizuRHistone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myelomaBlood201011640641720351311
   PubMed Web of Science ®Google Scholar
• OcioEMVilanovaDAtadjaPIn vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaHaematologica20109579480319951978
   PubMed Web of Science ®Google Scholar
• CampbellRASanchezESteinbergJVorinostat enhances the antimyeloma effects of melphalan and bortezomibEur J Haematol20108420121119929977
   PubMed Web of Science ®Google Scholar
• DuHLRenLMChenHZhuYQiYRe-expression of p16 gene in the myeloma cell line U266 induced by synergy of sodium butyrate and 5-Aza-2′-deoxycytidineDi Yi Jun Yi Da Xue Xue Bao20022298198412433622
   PubMedGoogle Scholar
• RamakrishnanVKimlingerTTimmMHaugJRajkumarSVKumarSMultiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001Leuk Res2014381358136625282334
   PubMed Web of Science ®Google Scholar
• ShimuraYKurodaJRiMRSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myelomaMol Cancer Ther201211122600260923012246
   PubMed Web of Science ®Google Scholar
• KaiserMLamottkeBMiethMSynergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myelomaEur J Haematol20108433734420028416
   PubMed Web of Science ®Google Scholar
• ChenSDaiYPeiXYGrantSBim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1Mol Cell Biol2009296149616919805519
   PubMed Web of Science ®Google Scholar
• FandyTEShankarSRossDDSausvilleESrivastavaRKInteractive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myelomaNeoplasia20057764665716026644
   PubMed Web of Science ®Google Scholar
• MagnerWJKazimALStewartCActivation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitorsJ Immunol2000165127017702411120829
   PubMed Web of Science ®Google Scholar
• SkovSPedersenMTAndresenLStratenPTWoetmannAOdumNCancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and BCancer Res20056523111361114516322264
   PubMed Web of Science ®Google Scholar
• KhanANGregorieCJTomasiTBHistone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cellsCancer Immunol Immunother200857564765418046553
   PubMed Web of Science ®Google Scholar
• ManningJIndrovaMLubyovaBInduction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumoursImmunology2008123221822717725605
   PubMed Web of Science ®Google Scholar
• ChristiansenAJWestABanksKMEradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodiesProc Natl Acad Sci U S A2011108104141414621368108
   PubMed Web of Science ®Google Scholar
• WestACMattarolloSRShorttJAn intact immune system is required for the anticancer activities of histone deacetylase inhibitorsCancer Res201373247265727624158093
   PubMed Web of Science ®Google Scholar
• SonnemannJGressmannSBeckerSWittigSSchmuddeMBeckJFThe histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitroCancer Chemother Pharmacol201066361161620221600
   PubMed Web of Science ®Google Scholar
• KroesenMGielenPBrokICArmandariIHoogerbruggePMAdemaGJHDAC inhibitors and immunotherapy; a double edged sword?Oncotarget20145166558657225115382
   PubMed Web of Science ®Google Scholar
• VoDDPrinsRMBegleyJLEnhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824Cancer Res200969228693869919861533
   PubMed Web of Science ®Google Scholar
• SongWTaiYTTianZHDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cellsLeukemia201125116116821102427
   PubMed Web of Science ®Google Scholar
• MannBSJohnsonJRCohenMHJusticeRPazdurRFDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphomaOncologist200712101247125217962618
   PubMed Web of Science ®Google Scholar
• RichardsonPMitsiadesCColsonKPhase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myelomaLeuk Lymphoma200849350250718297527
   PubMed Web of Science ®Google Scholar
• BadrosABurgerAMPhilipSPhase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myelomaClin Cancer Res200915165250525719671864
   PubMed Web of Science ®Google Scholar
• SiegelDSDimopoulosMAYoonS-SVantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b TrialASHSan Diego2011
   Google Scholar
• DimopoulosMASiegelDSLonialSVorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyLancet Oncol201314111129114024055414
   PubMed Web of Science ®Google Scholar
• AlsayedYNairBPKauffmanMCarfilzomib (CFZ) in combination with DEX and other agents (Dox, Thal, DDP, vorinostat) for far advanced and refractory multiple myeloma (FARMM)J Clin Oncol201028e18504 ASCO Annual Meeting Abstracts
   Web of Science ®Google Scholar
• SiegelDSRichardsonPDimopoulosMVorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myelomaBlood Cancer J20144e18224562384
   PubMed Web of Science ®Google Scholar
• WolfLWSiegelDMatousJA phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myelomaBlood200811112 ASH Annual Meeting Abstracts
   Google Scholar
• San-MiguelJFRichardsonPGGSezerOA phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myelomaJ Clin Oncol20112915 abstr8075. ASCO Annual Meeting Proceedings
   Web of Science ®Google Scholar
• RichardsonPGSchlossmanRLAlsinaMPANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myelomaBlood20131222331233723950178
   PubMed Web of Science ®Google Scholar
• San-MiguelJFHungriaVTMYoonSSPanobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialLancet Oncol2014151195120625242045
   PubMed Web of Science ®Google Scholar
• RichardsonPGHungriaVTMYoonSSPanobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatmentBlood2016127671372126631116
   PubMed Web of Science ®Google Scholar
• BertinoaEMOttersonaGARomidepsin: a novel histone deacetylase inhibitor for cancerExpert Opin Investig Drugs201120811511158
   Web of Science ®Google Scholar
• NiesvizkyRElySMarkTPhase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaCancer2011117233634220862746
   PubMed Web of Science ®Google Scholar
• HarrisonSJQuachHLinkEA high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myelomaBlood2011118246274628321911830
   PubMed Web of Science ®Google Scholar
• LunningMARuanJNairSA phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: phase I resultsJ Clin Oncol2014325 supplabstr8582
   Web of Science ®Google Scholar
• RajeNVoglDTHariPNACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)ASH 2013 Annual Meeting Abstract 759 (Oral Presentation)New Orleans, LA2013
   Google Scholar
• YeeAVorheesPBensingerWIACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b TrialASH 2013 Annual Meeting Abstract 3190 (Poster Presentation)New Orleans, LA2013
   Google Scholar
• SullivanDSSSchusterMBerensonJA phase II study of PXD 101 in advanced multiple myelomaBlood200611108 ASH Annual Meeting Abstracts
   Google Scholar
• GalliMSalmoiraghiSGolayJA phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myelomaAnn Hematol201089218519019633847
   PubMed Web of Science ®Google Scholar